View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2018	Aug. 09, 2018
Document Information [Line Items]
Entity Registrant Name	KEMPHARM, INC
Entity Central Index Key	0001434647
Trading Symbol	kmph
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		16,042,018
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Assets
Cash and cash equivalents	$ 16,497	$ 10,871
Restricted cash	1,100	1,100
Marketable securities	11,702	31,358
Trade date receivables		2,005
Prepaid expenses and other current assets	1,610	1,662
Total current assets	30,909	46,996
Property and equipment, net	1,841	2,004
Long-term investments		3,250
Other long-term assets	1,250	206
Total assets	34,000	52,456
Liabilities and stockholders' deficit
Accounts payable and accrued expenses	13,967	7,875
Current portion of convertible notes	3,333	3,333
Current portion of capital lease obligation	190	189
Other current liabilities	113	112
Total current liabilities	17,603	11,509
Convertible notes, less current portion, net	86,845	89,398
Derivative and warrant liability	11,888	7,709
Capital lease obligation, less current portion	466	562
Other long-term liabilities	743	794
Total liabilities	117,545	109,972
Commitments and contingencies (Note D)
Stockholders’ deficit:
Common stock, $0.0001 par value, 250,000,000 shares authorized, 15,905,146 shares issued and outstanding as of June 30, 2018 (unaudited); 14,657,430 shares issued and outstanding as of December 31, 2017	2	1
Additional paid-in capital	117,391	107,209
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding as of June 30, 2018 (unaudited) or December 31, 2017	0	0
Accumulated deficit	(200,938)	(164,726)
Total stockholders' deficit	(83,545)	(57,516)
Total liabilities and stockholders' deficit	$ 34,000	$ 52,456

Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2018	Dec. 31, 2017
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	15,905,146	14,657,430
Common stock, shares outstanding (in shares)	15,905,146	14,657,430
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

Unaudited Condensed Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenue
Operating expenses:
Research and development	10,488	4,650	22,125	8,764
General and administrative	3,420	3,574	6,552	6,840
Total operating expenses	13,908	8,224	28,677	15,604
Loss from operations	(13,908)	(8,224)	(28,677)	(15,604)
Other (expense) income:
Interest expense related to amortization of debt issuance costs and discount	(390)	(390)	(780)	(780)
Interest expense on principal	(1,419)	(1,443)	(2,861)	(2,884)
Fair value adjustment related to derivative and warrant liability	5,562	3,523	(4,179)	(3,693)
Interest and other income, net	123	13	238	114
Total other (expense) income	3,876	1,703	(7,582)	(7,243)
Loss before income taxes	(10,032)	(6,521)	(36,259)	(22,847)
Income tax benefit	39	4	47	8
Net loss	$ (9,993)	$ (6,517)	$ (36,212)	$ (22,839)
Net loss per share:
Basic (in dollars per share)	$ (0.65)	$ (0.44)	$ (2.41)	$ (1.56)
Diluted (in dollars per share)	$ (0.91)	$ (0.44)	$ (2.41)	$ (1.56)
Weighted average number of shares of common stock outstanding:
Basic (in shares)	15,317,536	14,649,586	15,056,161	14,648,291
Diluted (in shares)	16,548,751	14,649,586	15,056,161	14,648,291

Unaudited Condensed Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activities:
Net loss	$ (36,212)	$ (22,839)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	2,659	2,254
Non-cash interest expense	2,195	2,220
Amortization of debt issuance costs and debt discount	780	780
Depreciation and amortization expense	166	164
Fair value adjustment related to derivative and warrant liability	4,179	3,693
Loss on sublease		102
Change in assets and liabilities:
Prepaid expenses and other assets	(1,030)	(151)
Accounts payable and accrued expenses	4,063	(2,318)
Other liabilities	(51)	101
Net cash used in operating activities	(23,251)	(15,994)
Cash flows from investing activities:
Purchases of property and equipment		(143)
Purchases of marketable securities and long-term investments		(20,922)
Maturities and sales of marketable securities	24,911	32,806
Net cash provided by investing activities	24,911	11,741
Cash flows from financing activities:
Proceeds from at-the-market offering, net of commissions	3,992
Repayment of obligations under capital lease	(94)	(77)
Payment of deferred offering costs		(50)
Proceeds from exercise of common stock options	68	4
Net cash provided by (used in) financing activities	3,966	(123)
Net increase (decrease) in cash, cash equivalents and restricted cash	5,626	(4,376)
Cash, cash equivalents and restricted cash, beginning of period	11,971	17,862
Cash, cash equivalents and restricted cash, end of period	17,597	13,486
Supplemental cash flow information:
Cash paid for interest	2,863	2,857
Conversion of Deerfield Convertible Note principal and interest	3,502
Fixed assets financed under a lease agreement		284
Deferred offering costs included in accounts payable and accrued expenses		60
Fixed assets included in accounts payable and accrued expenses	$ 3	$ 7

Note A - Description of Business and Basis of Presentation

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Business Description and Basis of Presentation [Text Block]

A.	Description of Business and Basis of Presentation

Organization

KemPharm, Inc. (the “Company”) is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy ("LAT™") platform technology. The Company utilizes its proprietary LAT platform technology to generate improved prodrug versions of U.S. Food and Drug Administration (the "FDA") approved drugs in the high need areas of attention deficit hyperactivity disorder ("ADHD"), pain and other central nervous system ("CNS") disorders. The Company was formed and incorporated in Iowa on

October

30,

2006

and reorganized in Delaware on

May 30, 2014.

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for inter

im financial information and with the instructions to Form

-Q and Rule

of Regulation S-

Accordingly, they do

not

include all of the information and related notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included in the accompanying financial statements. Operating results for the

three

and

six

months ended

June 30, 2018

are

not

necessarily indicative of the results that

may

be expected for the full year ending

December 31, 2018.

This interim information should be read in conjunction with the audited financial statements included in the Company

’s Annual Report on Form

-K for the fiscal year ended

December 31, 2017,

filed with the Securities and Exchange Commission (“SEC”) on

March 30, 2018.

Going Concern

The unaudited condensed financial statements have been prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has experienced recurring losses from operations and negative operating cash flows due to its ongoing research and development of its product and product candidates. The Company also has an accumulated deficit as of

June 30, 2018.

Various internal and external factors will affect whether and when product candidates become approved drugs and how significant the market share of those approved products will be. The length of time and cost of developing and commercializing these product and product candidates and/or failure of them at any stage of the drug approval or commercialization process will materially affect the Company’s financial condition and future operations.

Management believes these conditions raise substantial doubt about the Company’s ability to continue as a going concern within the

twelve

months after the date these unaudited condensed financial statements are issued. The Company's ability to continue as a going concern is dependent upon profitable future operations, positive cash flows and additional financing.

Management intends to finance operating costs over the next

twelve

months with existing cash and cash equivalents and marketable securities, as well as, financing through the Company's active registration statement on Form S-

covering the sale of up to

$150.0

million of the Company's common stock, preferred stock, and debt and/or warrants. The registration statement on Form S-

included a prospectus covering the offering up to

$20,000,000

of shares of common stock through an "at-the-market offering."

Entry into ATM Agreement

October 3, 2016,

the Company entered into a Common Stock Sales Agreement (the “ATM Agreement”) with Cowen and Company, LLC (“Cowen”) under which the Company

may

offer and sell, from time to time, in its sole discretion, shares of common stock having an aggregate offering price of up to

$50,000,000

through Cowen as the Company's sales agent. The Company’s registration statement on Form S-

contemplated under the ATM Agreement was declared effective by the SEC on

October 17, 2016.

The registration statement on Form S-

included a prospectus covering the offering up to

$20,000,000

of shares of common stock in accordance with the ATM Agreement.

Cowen

may

sell common stock under the ATM Agreement by any method permitted by law deemed to be an “at the market offering” as defined in Rule

415

of the Securities Act or

1933,

as amended ("Securities Act"), including without limitation sales made by means of ordinary brokers’ transactions on the N

ASDAQ

Global Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise directed by the Company. Cowen will use commercially reasonable efforts to sell the common stock from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company

may

impose). The Company will pay Cowen a commission of up to

three

percent (

3.0%

) of the gross sales proceeds of any common stock sold through Cowen under the ATM Agreement, and also has provided Cowen with customary indemnification rights.

The Company is

not

obligated to make any sales of common stock under the ATM Agreement. The offering of shares of common stock pursuant to the ATM Agreement will terminate upon the earlier of (i) the sale of all common stock subject to the ATM Agreement, or (ii) termination of the ATM Agreement in accordance with its terms. As of

June 30, 2018,

the Company had deferred offering costs recorded within prepaid expenses and other current assets in the amount of

$0.2

million.

As of

June 30, 2018,

the Company has sold

625,466

shares of common stock under the ATM Agreement, resulting in gross proceeds of

$4.1

million.

Note B - Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Significant Accounting Policies [Text Block]

B.	Summary of Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

On an ongoing basis, the Company evaluates its estimates, including those related to the useful lives of property and equipment, and assumptions used for purposes of determining stock-based compensation, income taxes, and the fair value of the derivative and warrant liability, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.

Application of New or Revised Accounting Standards—Adopted

From time to time, the Financial Accounting Standards Board (the “FASB”) or other standard-setting bodies issue accounting standards that are adopted by the Company as of the specified effective date.

April 5, 2012,

President Obama signed the Jump-Start Our Business Startups Act (the “JOBS Act”) into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an emerging growth company. As an emerging growth company, the Company

could have

elected to adopt new or revised accounting standards when they become effective for non-public companies, which typically is later than public companies must adopt the standards. The Company has irrevocably elected

not

to take advantage of the extended transition period afforded by the JOBS Act and, as a result, will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies.

May 2014,

the FASB issued guidance codified in the Accounting Standards Codification ("ASC") Topic

606,

Revenue Recognition—Revenue from Contracts with Customers

("ASC

606"

), which amended the guidance in former ASC

605,

Revenue Recognition

, and became effective beginning

January 1, 2018.

This guidance did

not

have a material impact on the Company's financial statements and disclosures upon adoption since the Company is

not

generating revenue at this time.

January 2016,

the FASB issued Accounting Standards Update ("ASU")

2016

01,

Financial Instruments Overall – Recognition and Measurement of Financial Assets and Liabilities (Topic

825

)

(“ASU

2016

01”

), which provides several updates related to Topic

825

10.

This update applies to all entities that hold financial assets or owe financial liabilities. This guidance is effective for financial statements issued for fiscal years beginning after

December 15, 2017,

and interim periods within those fiscal years. The adoption of ASU

2016

did

not

have a material impact on the Company's financial statements and disclosures.

August 2016,

the FASB issued ASU

2016

15,

Statement of Cash Flows – Classification of Certain Cash Receipts and Cash Payments (Topic

230

)

(“ASU

2016

15”

), which addresses

eight

specific cash flow issues with the objective of reducing the existing diversity in practice. This update applies to all entities that are required to present a statement of cash flows under Topic

230.

This guidance is effective for financial statements issued for fiscal years beginning after

December 15, 2017,

and interim periods within those fiscal years. The adoption of ASU

2016

did

not

have a material impact on the Company's financial statements and disclosures.

May 2017,

the FASB issued ASU

2017

09,

Compensation – Stock Compensation (Topic

718

) – Scope of Modification Accounting

("ASU

2017

09"

), which provides guidance about which changes to the terms or conditions of a stock-based payment award require an entity to apply modification accounting in Topic

718.

This update applies to any entity that changes the terms or conditions of a stock-based payment award. This guidance is effective for financial statements issued for fiscal years beginning after

December 15, 2017,

and interim periods within those fiscal years. The adoption of ASU

2017

did

not

have a material impact on the Company's financial statements and disclosures.

Application of New or Revised Accounting Standards

—Not

Yet Adopted

February 2016,

the FASB issued ASU

2016

02,

Leases (Topic

842

)

(“ASU

2016

02”

), which requires lessees to recognize assets and liabilities for operating leases with lease terms greater than

twelve

months in the balance sheet. The update also requires improved disclosures to help users of financial statements better understand the amount, timing and uncertainty of cash flows arising from leases. ASU

2016

is effective for fiscal years beginning after

December 15, 2018,

including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of the adoption of ASU

2016

on its financial statements and disclosures.

July 2017,

the FASB issued ASU

2017

11,

Earnings Per Share (Topic

260

), Distinguishing Liabilities from Equity (Topic

480

), Derivatives and Hedging (Topic

815

) – I. Accounting for Certain Financial Instruments with Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception

("ASU

2017

11"

), which addresses the complexity of accounting for certain financial instruments with down round features and addresses the difficulty of navigating Topic

480

because of the existence of extensive pending content in the ASC as a result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling interests. This update applies to all entities that issue financial instruments that include down round features and entities that present earnings per share in accordance with Topic

260.

This guidance is effective for financial statements issued for fiscal years beginning after

December 15, 2018,

and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. If early adopted in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating the impact of the adoption of ASU

2017

on its financial statements and disclosures.

Note C - Debt Obligations

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Debt Disclosure [Text Block]

C.	Debt Obligations

Deerfield Facility Agreement

June

2014,

the Company entered into a

$60

million facility agreement (the “Deerfield Facility Agreement”) with Deerfield Private Design Fund III, LP (“Deerfield”). The

first

payment to the Company under the terms of the Deerfield Facility Agreement consisted of a term loan of

$15

million (the “Term Note”) and a senior secured loan of

$10

million (the “Deerfield Convertible Note”). As of

June 30, 2016,

Deerfield was

longer obligated to provide the Company any additional disbursements under the Deerfield Facility Agreement. All loans issued under the Deerfield Facility Agreement bear interest at

9.75%

per annum. Deerfield

may

convert any portion of the outstanding principal and any accrued but unpaid interest on the Deerfield Convertible Note into shares of the Company’s common stock at an initial conversion price of

$5.85

per share (the "Deerfield Note Put Option").

The Company also issued to Deerfield a warrant to purchase

14,423,076

shares of Series D redeemable convertible preferred stock (“Series D Preferred”) at an exercise price of

$0.78

per share, which is exercisable until

June

2024

(the “Deerfield Warrant”). Upon completion of the Company's initial public offering (the "IPO"), the Deerfield Warrant automatically converted into a warrant to purchase

1,923,077

shares of the Company’s common stock at an exercise price of

$5.85

per share. This warrant qualifies as a participating security under ASC Topic

260,

Earnings per Share,

and is treated as such in the net loss per share calculation (Note I). If a Major Transaction occurs, as defined below, Deerfield

may

require the Company to redeem the Deerfield Warrant for a cash amount equal to the Black-Scholes value of the portion of the Deerfield Warrant to be redeemed (the “Warrant Put Option”). A Major Transaction is (i) a consolidation, merger, exchange of shares, recapitalization, reorganization, business combination or other similar event; (ii) the sale or transfer in

one

transaction or a series of related transactions of all or substantially all of the assets of the Company; (iii) a

third

-party purchase, tender or exchange offer made to the holders of outstanding shares, such that following such purchase, tender or exchange offer a change of control has occurred; (iv) the liquidation, bankruptcy, insolvency, dissolution or winding-up affecting the Company; (v) the shares of the Company’s common stock cease to be listed on any eligible market; and (vi) at any time, the shares of the Company’s common stock cease to be registered under Section

of the Securities Exchange Act of

1934,

as amended (the “Exchange Act”).

In addition, the Company issued to Deerfield

1,923,077

shares of Series D Preferred as consideration for the loans provided to the Company under the Deerfield Facility Agreement. Upon completion of the IPO, these shares automatically reclassified into

256,410

shares of the Company’s common stock. The Company recorded the fair value of the shares of Series D Preferred of

$1.5

million, to debt issuance costs on the date of issuance. The Company recorded the fair value of the Deerfield Warrant and the embedded Warrant Put Option to debt discount on the date of issuance. The debt issuance costs and debt discount are amortized over the term of the related debt and the expense is recorded as interest expense related to amortization of debt issuance costs and discount in the statements of operations.

Pursuant to the Deerfield Facility Agreement, the Company

may

not

enter into specified transactions, including a debt financing in the aggregate value of

$750,000

or more, a merger, an asset sale or any other change of control transaction or any joint venture, partnership or other profit sharing arrangement, without the prior approval of Deerfield. Additionally, if the Company were to enter into a major transaction, including a merger, consolidation, sale of substantially all of its assets or other change of control transaction, Deerfield would have the ability to demand that prior to consummation of such transaction the Company repay all outstanding principal and accrued interest of any notes issued under the Deerfield Facility Agreement. Under each warrant issued pursuant to the Deerfield Facility Agreement, Deerfield has the right to demand that the Company redeem the warrant for a cash amount equal to the Black-Scholes value of a portion of the warrant upon the occurrence of specified events, including a merger, an asset sale or any other change of control transaction.

The Company must repay

one

third

of the outstanding principal amount of all debt issued under the Deerfield Facility Agreement on the

fourth

and

fifth

anniversaries of the Deerfield Facility Agreement. The Company is then also obligated to repay the balance of the outstanding principal amount on

February

14,

2020.

The Company prepaid all outstanding interest and principal on the Term Note in

February 2016. The outstanding principal amount due on the fourth anniversary of the Deerfield Facility Agreement and the related accrued but unpaid interest as of such date was converted in common stock of the Company in accordance with the provisions of the Deerfield Convertible Note. Refer to the section entitled Facility Agreement Waiver and Fifth Amendment to Senior Secured Convertible Note below.

Interest accrued on outstanding debt under the Deerfield Facility Agreement is due quarterly in arrears. Upon notice to Deerfield, the Company had the option to have

one

or more of the

first

eight

of such scheduled interest payments added to the outstanding principal amount of the debt issued under the Deerfield Facility Agreement, provided that all such interest was due on

July

2016.

The Company elected this option on all

eight

of the scheduled interest payments through

June 30, 2016.

The accrued interest added to outstanding principal, was paid to Deerfield on

July 1, 2016.

In connection with the IPO, on

March 6, 2015,

the Company entered into a First Amendment (the “First Amendment) to the Deerfield Facility Agreement, the Deerfield Convertible Note and Deerfield Warrant, by and between the Company and Deerfield. The First Amendment, among other things, clarified that all references to the conversion of shares of Series D Preferred into the Company’s common stock in the Deerfield Facility Agreement, the Deerfield Convertible Note and Deerfield Warrant shall include any reclassification of the outstanding shares of Series D Preferred into shares of the Company’s common stock

Second Amendment to Senior Secured Convertible Note and Warrant

January 6, 2016,

the Company entered into a Second Amendment (the “Second Amendment”) to the Deerfield Convertible Note and Deerfield Warrant, by and between the Company and Deerfield. The Second Amendment, among other things, clarified the calculation of an anti-dilution adjustment of the conversion price and exercise price of the Deerfield Convertible Note and Deerfield Warrant, respectively, in the event that the Company effects a firm commitment underwritten public offering of its securities.

Issuance of

5.50%

Senior Convertible Notes and Third Amendment to Facility Agreement, Senior Secured Convertible Note and Warrant

February 9, 2016,

the Company issued

$86.3

million aggregate principal amount of its

5.50%

Senior Convertible Notes due

2021

(the

“2021

Notes”) to Cowen and RBC Capital Markets, LLC, as representatives of the several initial purchasers (the “Initial Purchasers”), who subsequently resold the

2021

Notes to qualified institutional buyers (the “Note Offering”) in reliance on the exemption from registration provided by Rule

144A

under the Securities Act.

The net proceeds from the Note Offering were approximately

$82.8

million, after deducting the Initial Purchasers’ discount and estimated offering expenses. Concurrent with the Note Offering, the Company used approximately

$18.6

million of the net proceeds from the Note Offering to repay in full the Term Note, plus all accrued but unpaid interest, a make-whole interest payment and a prepayment premium on the Term Note. This principal, accrued but unpaid interest, make-whole interest payment and prepayment premium on the Term Note is reflected as a cash outflow from financing activity in the statements of cash flows.

The

2021

Notes were issued pursuant to an Indenture, dated as of

February

2016

(the “Indenture”), between the Company and U.S. Bank National Association, as trustee. Interest on the

2021

Notes is payable semi-annually in cash in arrears on

February

and

August

of each year, beginning on

August

2016,

at a rate of

5.50%

per year. The

2021

Notes mature on

February

2021

unless earlier converted or repurchased. The

2021

Notes are

not

redeemable prior to the maturity date, and

sinking fund is provided for the

2021

Notes.

The

2021

Notes are convertible at an initial conversion rate of

58.4454

shares of the Company’s common stock per

$1,000

principal amount of the

2021

Notes, subject to adjustment under the Indenture, which is equal to an initial conversion price of approximately

$17.11

per share of common stock. Upon conversion, the

2021

Notes will be settled in shares of the Company’s common stock, together with a cash payment in lieu of delivering any fractional share. The conversion rate will be subject to adjustment in some events but will

not

be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its

2021

Notes in connection with such a corporate event in certain circumstances.

If the Company undergoes a “fundamental change” (as defined in the Indenture), holders

may

require that the Company repurchase for cash all or any portion of their

2021

Notes at a fundamental change repurchase price equal to

100%

of the principal amount of the

2021

Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, holders who convert their

2021

Notes on or after the date that is

one

year after the last date of original issuance of the

2021

Notes

may

also be entitled to receive, under certain circumstances, an interest make-whole payment payable in shares of the Company’s common stock. The Company is bifurcating the fundamental change and make-whole interest payment provisions as embedded derivatives and marking them to fair value each reporting period (Note H).

The Indenture includes customary terms and covenants, including certain events of default after which the

2021

Notes

may

be due and payable immediately.

In connection with the Note Offering, on

February 3, 2016,

the Company entered into a Third Amendment (the “Third Amendment”) to the Deerfield Facility Agreement, Deerfield Convertible Note and Deerfield Warrant with Deerfield. The Third Amendment, among other things, eliminated the Company’s ability to require Deerfield to convert the Deerfield Convertible Note into Company common stock. In addition, pursuant to the Third Amendment, Deerfield consented to the prepayment of the Term Note and the issuance of the

2021

Notes.

Fourth Amendment to Senior Secured Convertible Note and Warrant

In connection with entering into the ATM Agreement, on

October 3, 2016,

the Company entered into a Fourth Amendment (the “Fourth Amendment”) to the Deerfield Convertible Note and the Deerfield Warrant with Deerfield. The Fourth Amendment, among other things, clarifies the calculation of an anti-dilution adjustment of the conversion price and exercise price of the Deerfield Convertible Note and Deerfield Warrant, respectively, in the event that the Company effects an “at the market offering” as defined in Rule

415

of the Securities Act of its common stock.

Facility Agreement Waiver and Fifth Amendment to Senior Secured Convertible Note

June 11, 2018,

the Company entered into the Facility Agreement Waiver and Fifth Amendment (the "Fifth Amendment") to the Deerfield Convertible Note with Deerfield. The Fifth Amendment, among other things, provided that (i)

$3,333,333

of the principal amount, plus

$168,288

of accrued interest, of the Deerfield Convertible Note issued pursuant to the terms of the Deerfield Facility Agreement was converted into

598,568

shares of the Company’s common stock, with such principal conversion amount being applied against and in full satisfaction of the amortization payment due

June 2, 2018; (

ii) Deerfield waived specified rights under the Deerfield Facility Agreement with regards to such principal and interest amount; and (iii) amended specified provisions of the Deerfield Convertible Note as they relate to the delivery of shares of the Company’s common stock in connection with any conversion of the Deerfield Convertible Note.

Except as modified by the First Amendment, Second Amendment, Third Amendment, Fourth Amendment and Fifth Amendment, all terms and conditions of the Deerfield Facility Agreement, Deerfield Warrant and Deerfield Convertible Note remained in full force and effect.

Line of Credit

During the

second

quarter of

2016,

the Company opened a line of credit with a total borrowing capacity of

$1.1

million with City National Bank of Florida (the "Line of Credit Agreement") to support several irrevocable letters of credit issued by the bank on behalf of the Company. As of June

30, 2018

, the Company had unused letters of credit in the amount of

$0.4

million. The line of credit had a maturity date of

January 31, 2018.

January 31, 2018,

the line of credit was renewed for an additional

two

-year term and will now mature on

January 31, 2020.

As of

June 30, 2018

, the Company had

outstanding balances under the line of credit. The Line of Credit Agreement is collateralized by a restricted money market account, equal to the total amount of the borrowing capacity under the line of credit, held by the same bank institution. The money market account is reported as restricted cash on the condensed balance sheets. The line of credit contains

financial covenants. Borrowings under the Line of Credit Agreement carry interest at a rate equal to the

-month London Interbank Offered Rate plus

2.00%

per annum. The interest rate under the Line of Credit Agreement was

3.98

% as of

June 30, 2018.

Note D - Commitments and Contingencies

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

D.	Commitments and Contingencies

From time to time, the Company is involved in various legal proceedings arising in the normal course of business. For some matters, a liability is

not

probable, or the amount cannot be reasonably estimated and, therefore, an accrual has

not

been made. However, for such matters when it is probable that the Company has incurred a liability and can reasonably estimate the amount, the Company accrues and discloses such estimates. As of

June 30, 2018

and

December 31,

2017,

accruals have been made related to commitments and contingencies.

December 2016,

a class action suit was filed against the Company in the Iowa District Court in Johnson County by a stockholder alleging that the Company, certain of its senior executives and directors who signed the registration statement in connection with its IPO, and each of the investment banks that acted as underwriters for the offering negligently issued untrue statements of material facts and omitted to state material facts required to be stated in the registration statement and incorporated offering materials that the Company filed with the SEC in support of the offering.

June 27, 2018,

the Iowa District Court dismissed the case without prejudice to members of the putative class.

Note E - Preferred Stock and Warrants

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Preferred Stock [Text Block]

E.	Preferred Stock and Warrants

Authorized, Issued, and Outstanding Preferred Stock

As of

June 30

, 2018 and 2017,

the Company had

10,000,000

shares of authorized and undesignated preferred stock, and did

not

have any preferred stock outstanding.

Warrants

During

2013,

the Company issued

$3.8

million of convertible notes and the warrants (the

“2013

Warrants”) to purchase

1,079,453

shares of equity securities in a future financing meeting specified requirements (a “Qualified Financing”). The

2013

Warrants allow the holders to purchase shares of the same class and series of equity securities issued in the Qualified Financing for an exercise price equal to the per share price paid by the purchasers of such equity securities in the Qualified Financing. When the Company entered into the Deerfield Facility Agreement, the

2013

Warrants became warrants to purchase

1,079,453

shares of Series D Preferred. Upon completion of the IPO, the

2013

Warrants automatically converted into warrants to purchase

143,466

shares of the Company’s common stock at an exercise price of

$5.85

per share. The

2013

Warrants, if unexercised, expire on the earlier of

June 2, 2019,

or upon a liquidation event.

June 2, 2014,

pursuant to the terms of the Deerfield Facility Agreement, the Company issued the Deerfield Warrant to purchase

14,423,076

shares of Series D Preferred (Note C). The Company recorded the fair value of the Deerfield Warrant as a debt discount and a warrant liability. The Deerfield Warrant, if unexercised, expires on the earlier of

June 2, 2024,

or upon a liquidation event. Upon completion of the IPO, the Deerfield Warrant automatically converted into a warrant to purchase

1,923,077

shares of the Company’s common stock at an exercise price of

$5.85

per share. The Company is amortizing the debt discount over the term of the Deerfield Convertible Note and the expense is recorded as interest expense related to amortization of debt issuance costs and discount in the condensed statements of operations.

The Company determined that the

2013

Warrants and Deerfield Warrant should be recorded as a liability and stated at fair value at each reporting period upon inception. As stated above, upon completion of the IPO, the

2013

Warrants and the Deerfield Warrant automatically converted into warrants to purchase the Company’s common stock. The Company marked the

2013

Warrants to fair value and reclassified them to equity upon closing of the IPO. The Deerfield Warrant remains classified as a liability and is recorded at fair value at each reporting period since it can be settled in cash. Changes to the fair value of the warrant liability are recorded through the condensed statements of operations as a fair value adjustment (Note H).

Note F - Common Stock and Warrants

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

F.	Common Stock and Warrants

Authorized,

Issued, and Outstanding Common Shares

April 2015,

the Company amended and restated its Certificate of Incorporation to increase the number of its authorized shares of common stock to

250,000,000

shares. Of the authorized shares,

15,905,146

and

14,657,430

shares of common stock were issued and outstanding as of

June 30, 2018

and

December 31, 2017,

respectively.

As of

June 30, 2018

and

December 31,

2017,

the Company had reserved authorized shares of common stock for future issuance as follows:

	June 30, 2018		December 31, 2017
Conversion of Deerfield Convertible Note		1,148,124		1,751,410
Conversion of 2021 Notes		5,040,914		5,040,914
Outstanding awards under equity incentive plans		3,682,996		2,853,924
Outstanding common stock warrants		2,027,763		2,027,763
Possible future issuances under equity incentive plans		675,897		944,700
Total common shares reserved for future issuance		12,575,694		12,618,711

Common Stock Activity

The following table summarizes common stock activity for the

six

months ended

June 30, 2018:

	Shares of Common Stock
Balance as of December 31, 2017		14,657,430
Common stock sold under the ATM Agreement		625,466
Common stock issued as a result of Deerfield Convertible Note principal and interest conversion		598,568
Common stock options exercised		23,682
Balance as of June 30, 2018		15,905,146

As of

June 30, 2018,

the Company has sold

625,466

shares of common stock under the ATM Agreement, resulting in gross proceeds of

$4.1

million.

Note G - Stock-based Compensation

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

G.	Stock-Based Compensation

The Company maintains a stock-based compensation plan (the “

Incentive Stock Plan”) that governs stock awards made to employees and directors prior to completion of the IPO.

November 2014,

the Board of Directors of the Company ("the Board"), and in

April 2015,

the Company’s stockholders, approved the Company’s

2014

Equity Incentive Plan (the

“2014

Plan”), which became effective in

April 2015.

The

2014

Plan provides for the grant of stock options, other forms of equity compensation, and performance cash awards. The maximum number of shares of common stock that

may

be issued under the

2014

Plan is

4,018,480

as of

June 30, 2018.

The number of shares of common stock reserved for issuance under the

2014

Plan will automatically increase on

January 1

of each year, beginning on

January 1, 2016,

and ending on and including

January 1, 2024,

of the total number of shares of the Company’s capital stock outstanding on

December 31

of the preceding calendar year, or a lesser number of shares determined by the Board. Pursuant to the terms of the

2014

Plan, on

January 1, 2018,

the common stock reserved for issuance under the

2014

Plan automatically increased by

586,297

shares.

During the

three

and

six

months ended June

30,

2018

, stock options were exercised for a total of

22,375

and

23,682

shares of common stock, respectively. During the

three

and

six

months ended June

30,

2017,

stock options were exercised for a total of

9,750

shares of common stock.

Stock-based compensation expense recorded under the Incentive Stock Plan

and the

2014

Plan is included in the following line items in the accompanying condensed statements of operations (in thousands):

	Three months ended June 30,				Six months ended June 30 ,
	2018		2017		2018		2017
Research and development	$	412	$	340	$	787	$	631
General and administrative		968		825		1,872		1,623
Total stock-based compensation expense		1,380		1,165		2,659	$	2,254

There was

stock-based compensation expense related to performance-based awards recognized during the

three

six

months ended

June 30, 2018

2017

Note H - Fair Value of Financial Instruments

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Fair Value Disclosures [Text Block]

H.	Fair Value of Financial Instruments

The accounting standard for fair value measurements provides a framework for measuring fair value and requires disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability.

The Company uses a

three

-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The

three

tiers are defined as follows:

	●	Level 1 —Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;

	●	Level 2 —Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and

	●	Level 3 —Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions.

The carrying amounts of certain financial instruments, including cash and cash equivalents, restricted cash and accounts payable, approximate their respective fair values due to the short-term nature of such instruments.

The fair value of the Deerfield Convertible Note was

$8.6

million and

$11.0

million, respectively, as of

June

30,

2018

and

December 31,

2017.

The fair value of the

2021

Notes was

$60.5

million and

$51.9

million, respectively, as of

June 30, 2018

and

December 31, 2017.

Both the Deerfield Convertible Note and

2021

Notes fall within Level

of the fair value hierarchy as their value is based on the credit worthiness of the Company, which is an unobservable input. The Company used a Tsiveriotis-Fernandes model to value the Deerfield Convertible Note and

2021

Notes as of

June 30, 2018

and

December 31, 2017.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. The following table summarizes the conclusions reached regarding fair value measurements as of

June 30, 2018

and

December 31, 2017 (

in thousands):

	Balance as of June 30, 2018		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Deerfield Warrant liability	$	8,461	$	—	$	—	$	8,461
Embedded Warrant Put Option		577		—		—		577
Fundamental change and make-whole interest provisions embedded in 2021 Notes		26		—		—		26
Embedded Deerfield Note Put Option		2,824		—		—		2,824
Total liabilities	$	11,888	$	—	$	—	$	11,888
Trading securities:
Certificates of deposit	$	1,217	$	1,217	$	—	$	—
U.S. Treasury securities		10,485		10,485		—		—
Total assets	$	11,702	$	11,702	$	—	$	—

	Balance as of December 31, 2017		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Deerfield Warrant liability	$	5,115	$	—	$	—	$	5,115
Embedded Warrant Put Option		365		—		—		365
Fundamental change and make-whole interest provisions embedded in 2021 Notes		14		—		—		14
Embedded Deerfield Note Put Option		2,215		—		—		2,215
Total liabilities	$	7,709	$	—	$	—	$	7,709
Trading securities:
Certificates of deposit	$	5,616	$	5,616	$	—	$	—
U.S. Treasury securities		25,988		25,988		—		—
U.S. government-sponsored agency securities		3,004		—		3,004		—
Total assets	$	34,608	$	31,604	$	3,004	$	—

The Company’s Deerfield Warrant liability, embedded Warrant Put Option, the fundamental change and the make-whole interest provisions embedded in the

2021

Notes and the embedded Deerfield Note Put Option, as well as the trading securities are measured at fair value on a recurring basis. As of

June 30, 2018 and December 31, 2017,

the Deerfield Warrant liability, embedded Warrant Put Option, the fundamental change and make-whole interest provisions embedded in the

2021

Notes, and the embedded Deerfield Note Put Option are reported on the condensed balance sheets in derivative and warrant liability, while the trading securities are reported on the condensed balance sheets in marketable securities and long-term investments.

The Company used a Monte Carlo simulation to value the Deerfield Warrant liability, embedded Warrant Put Option, the fundamental change and make-whole interest provisions embedded in the

2021

Notes, and the embedded Deerfield Note Put Option as of

June 30, 2018 and December 31, 2017.

Significant unobservable inputs used in measuring the fair value of these financial instruments included the Company’s estimated enterprise value, an estimate of the timing of a liquidity or fundamental change event, a present value discount rate and an estimate of the Company’s stock volatility using the volatilities of guideline peer companies. Changes in the fair value of the Deerfield Warrant liability, embedded Warrant Put Option, the fundamental change and make-whole interest provisions embedded in the

2021

Notes, and the embedded Deerfield Note Put Option are reflected in the condensed statements of operations for the

three

and

six

months ended

June 30, 2018 and 2017

as a fair value adjustment related to derivative and warrant liability.

A reconciliation of the beginning and ending balances for the derivative and warrant liability measured at fair value on a recurring basis using significant unobservable inputs (Level

) is as follows (in thousands):

	Three months ended June 30,						Six months ended June 30,
	2018			2017			2018		2017
Balance as of beginning of period	$	17,450		$	11,834		$	7,709	$	4,618
Adjustment to fair value		(5,562	)		(3,523	)		4,179		3,693
Balance as of end of period	$	11,888		$	8,311		$	11,888	$	8,311

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Note I - Net Earnings Per Share

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Earnings Per Share [Text Block]

I.	Net Earnings Per Share

Under the

two

-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current year earnings that participating securities would have been entitled to receive pursuant to their dividend rights had all of the year’s earnings been distributed.

such adjustment to earnings is made during periods with a net loss as the holders of the participating securities have

obligation to fund losses. Diluted net earnings per common share is computed under the

two

-class method by using the weighted average number of shares of common stock outstanding plus, for periods with net income attributable to common stockholders, the potential dilutive effects of stock options and warrants. In addition, the Company analyzes the potential dilutive effect of the outstanding participating securities under the if-converted method when calculating diluted earnings per share in which it is assumed that the outstanding participating securities convert into common stock at the beginning of the period. The Company reports the more dilutive of the approaches (

two

-class or if-converted) as its diluted net earnings per share during the period.

Diluted net loss per share

was the same as basic net loss per share for the

six

months ended

June 30, 2018

and the

three

and

six

months ended

June 30, 2017,

because the effects of potentially dilutive items were anti-dilutive for the respective periods. The following securities, presented on a common stock equivalent basis, have been excluded from the calculation of weighted average number of shares of common stock outstanding because their effect is anti-dilutive:

	Three months ended June 30,				Six months ended June 30,
	2018		2017		2018		2017
Warrants to purchase common stock		104,686		2,027,763		2,027,763		2,027,763
Awards under equity incentive plans		3,682,996		2,873,344		3,682,996		2,873,344
Deerfield Convertible Note		—		1,750,954		1,148,124		1,750,954
2021 Notes		5,040,914		5,040,914		5,040,914		5,040,914
Total securities excluded from the calculation of weighted average number of shares of common stock outstanding		8,828,596		11,692,975		11,899,797		11,692,975

The following table reconciles basic net loss per share of common stock to diluted net loss per share of common stock for the

three

months ended

June 30, 2018 (

in thousands, except per share data):

	Three months ended
	June 30, 2018
Basic net loss per share of common stock:
Net loss	$	(9,993	)
Less: Net loss allocable to participating securities		—
Net loss allocable to shares of common stock		(9,993	)
Less: Dividends declared or accumulated		—
Undistributed net loss allocable to shares of common stock, basic	$	(9,993	)
Weighted average number of shares of common stock outstanding		15,318
Basic net loss per share of common stock	$	(0.65	)
Diluted net loss per share of common stock:
Net loss	$	(9,993	)
Less: Fair value adjustment income related to Deerfield Warrant liability		(2,615	)
Add back: Total interest expense related to Deerfield Convertible Note		409
Less: Fair value adjustment income related to embedded Deerfield Note Put Option		(2,923	)
Net loss allocable to shares of common stock, diluted	$	(15,122	)
Weighted average number of shares of common stock outstanding		15,318
Dilutive effect of Deerfield Warrant		79
Dilutive effect of Deerfield Convertible Note		1,152
Weighted average number of shares of common stock outstanding, diluted		16,549
Diluted net loss per share of common stock	$	(0.91	)

Significant Accounting Policies (Policies)	6 Months Ended
Significant Accounting Policies (Policies)	Jun. 30, 2018
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates, including those related to the useful lives of property and equipment, and assumptions used for purposes of determining stock-based compensation, income taxes, and the fair value of the derivative and warrant liability, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.
New Accounting Pronouncements, Policy [Policy Text Block]	Application of New or Revised Accounting Standards—Adopted From time to time, the Financial Accounting Standards Board (the “FASB”) or other standard-setting bodies issue accounting standards that are adopted by the Company as of the specified effective date. On April 5, 2012, President Obama signed the Jump-Start Our Business Startups Act (the “JOBS Act”) into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an emerging growth company. As an emerging growth company, the Company could have elected to adopt new or revised accounting standards when they become effective for non-public companies, which typically is later than public companies must adopt the standards. The Company has irrevocably elected not to take advantage of the extended transition period afforded by the JOBS Act and, as a result, will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. In May 2014, the FASB issued guidance codified in the Accounting Standards Codification ("ASC") Topic 606, Revenue Recognition—Revenue from Contracts with Customers ("ASC 606" ), which amended the guidance in former ASC 605, Revenue Recognition , and became effective beginning January 1, 2018. This guidance did not have a material impact on the Company's financial statements and disclosures upon adoption since the Company is not generating revenue at this time. In January 2016, the FASB issued Accounting Standards Update ("ASU") 2016 - 01, Financial Instruments Overall – Recognition and Measurement of Financial Assets and Liabilities (Topic 825 - 10 ) (“ASU 2016 - 01” ), which provides several updates related to Topic 825 - 10. This update applies to all entities that hold financial assets or owe financial liabilities. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The adoption of ASU 2016 - 01 did not have a material impact on the Company's financial statements and disclosures. In August 2016, the FASB issued ASU 2016 - 15, Statement of Cash Flows – Classification of Certain Cash Receipts and Cash Payments (Topic 230 ) (“ASU 2016 - 15” ), which addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This update applies to all entities that are required to present a statement of cash flows under Topic 230. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The adoption of ASU 2016 - 15 did not have a material impact on the Company's financial statements and disclosures. In May 2017, the FASB issued ASU 2017 - 09, Compensation – Stock Compensation (Topic 718 ) – Scope of Modification Accounting ("ASU 2017 - 09" ), which provides guidance about which changes to the terms or conditions of a stock-based payment award require an entity to apply modification accounting in Topic 718. This update applies to any entity that changes the terms or conditions of a stock-based payment award. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The adoption of ASU 2017 - 09 did not have a material impact on the Company's financial statements and disclosures.
New Accounting Pronouncements, Not Yet Adopted, Policy [Policy Text Block]	Application of New or Revised Accounting Standards —Not Yet Adopted In February 2016, the FASB issued ASU 2016 - 02, Leases (Topic 842 ) (“ASU 2016 - 02” ), which requires lessees to recognize assets and liabilities for operating leases with lease terms greater than twelve months in the balance sheet. The update also requires improved disclosures to help users of financial statements better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016 - 02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of the adoption of ASU 2016 - 02 on its financial statements and disclosures. In July 2017, the FASB issued ASU 2017 - 11, Earnings Per Share (Topic 260 ), Distinguishing Liabilities from Equity (Topic 480 ), Derivatives and Hedging (Topic 815 ) – I. Accounting for Certain Financial Instruments with Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception ("ASU 2017 - 11" ), which addresses the complexity of accounting for certain financial instruments with down round features and addresses the difficulty of navigating Topic 480 because of the existence of extensive pending content in the ASC as a result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling interests. This update applies to all entities that issue financial instruments that include down round features and entities that present earnings per share in accordance with Topic 260. This guidance is effective for financial statements issued for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. If early adopted in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating the impact of the adoption of ASU 2017 - 11 on its financial statements and disclosures.

Note F - Common Stock and Warrants (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Authorized Shares of Common Stock Reserved for Future Issuance [Table Text Block]

	June 30, 2018		December 31, 2017
Conversion of Deerfield Convertible Note		1,148,124		1,751,410
Conversion of 2021 Notes		5,040,914		5,040,914
Outstanding awards under equity incentive plans		3,682,996		2,853,924
Outstanding common stock warrants		2,027,763		2,027,763
Possible future issuances under equity incentive plans		675,897		944,700
Total common shares reserved for future issuance		12,575,694		12,618,711

Schedule of Common Stock Outstanding Roll Forward [Table Text Block]

	Shares of Common Stock
Balance as of December 31, 2017		14,657,430
Common stock sold under the ATM Agreement		625,466
Common stock issued as a result of Deerfield Convertible Note principal and interest conversion		598,568
Common stock options exercised		23,682
Balance as of June 30, 2018		15,905,146

Note G - Stock-based Compensation (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

	Three months ended June 30,				Six months ended June 30 ,
	2018		2017		2018		2017
Research and development	$	412	$	340	$	787	$	631
General and administrative		968		825		1,872		1,623
Total stock-based compensation expense		1,380		1,165		2,659	$	2,254

Note H - Fair Value of Financial Instruments (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	Balance as of June 30, 2018		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Deerfield Warrant liability	$	8,461	$	—	$	—	$	8,461
Embedded Warrant Put Option		577		—		—		577
Fundamental change and make-whole interest provisions embedded in 2021 Notes		26		—		—		26
Embedded Deerfield Note Put Option		2,824		—		—		2,824
Total liabilities	$	11,888	$	—	$	—	$	11,888
Trading securities:
Certificates of deposit	$	1,217	$	1,217	$	—	$	—
U.S. Treasury securities		10,485		10,485		—		—
Total assets	$	11,702	$	11,702	$	—	$	—

	Balance as of December 31, 2017		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Deerfield Warrant liability	$	5,115	$	—	$	—	$	5,115
Embedded Warrant Put Option		365		—		—		365
Fundamental change and make-whole interest provisions embedded in 2021 Notes		14		—		—		14
Embedded Deerfield Note Put Option		2,215		—		—		2,215
Total liabilities	$	7,709	$	—	$	—	$	7,709
Trading securities:
Certificates of deposit	$	5,616	$	5,616	$	—	$	—
U.S. Treasury securities		25,988		25,988		—		—
U.S. government-sponsored agency securities		3,004		—		3,004		—
Total assets	$	34,608	$	31,604	$	3,004	$	—

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	Three months ended June 30,						Six months ended June 30,
	2018			2017			2018		2017
Balance as of beginning of period	$	17,450		$	11,834		$	7,709	$	4,618
Adjustment to fair value		(5,562	)		(3,523	)		4,179		3,693
Balance as of end of period	$	11,888		$	8,311		$	11,888	$	8,311

Note I - Net Earnings Per Share (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	Three months ended June 30,				Six months ended June 30,
	2018		2017		2018		2017
Warrants to purchase common stock		104,686		2,027,763		2,027,763		2,027,763
Awards under equity incentive plans		3,682,996		2,873,344		3,682,996		2,873,344
Deerfield Convertible Note		—		1,750,954		1,148,124		1,750,954
2021 Notes		5,040,914		5,040,914		5,040,914		5,040,914
Total securities excluded from the calculation of weighted average number of shares of common stock outstanding		8,828,596		11,692,975		11,899,797		11,692,975

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three months ended
	June 30, 2018
Basic net loss per share of common stock:
Net loss	$	(9,993	)
Less: Net loss allocable to participating securities		—
Net loss allocable to shares of common stock		(9,993	)
Less: Dividends declared or accumulated		—
Undistributed net loss allocable to shares of common stock, basic	$	(9,993	)
Weighted average number of shares of common stock outstanding		15,318
Basic net loss per share of common stock	$	(0.65	)
Diluted net loss per share of common stock:
Net loss	$	(9,993	)
Less: Fair value adjustment income related to Deerfield Warrant liability		(2,615	)
Add back: Total interest expense related to Deerfield Convertible Note		409
Less: Fair value adjustment income related to embedded Deerfield Note Put Option		(2,923	)
Net loss allocable to shares of common stock, diluted	$	(15,122	)
Weighted average number of shares of common stock outstanding		15,318
Dilutive effect of Deerfield Warrant		79
Dilutive effect of Deerfield Convertible Note		1,152
Weighted average number of shares of common stock outstanding, diluted		16,549
Diluted net loss per share of common stock	$	(0.91	)

Note A - Description of Business and Basis of Presentation (Details Textual) - USD ($)	6 Months Ended	21 Months Ended
	Jun. 30, 2018	Jun. 30, 2018	Oct. 17, 2016	Oct. 03, 2016
Sale of Securities, Value, Available to Issue	$ 150,000,000	$ 150,000,000
Sale of Stock, Value, Available to Issue	$ 20,000,000	20,000,000
Stock Issued During Period, Shares, New Issues	625,466
Other Noncurrent Assets [Member]
Deferred Offering Costs	$ 200,000	$ 200,000
Cowen and Company, LLC [Member]
Sale of Stock, Authorized Offering Price			$ 20,000,000
Sale of Stock, Commission Fee			3.00%
Stock Issued During Period, Shares, New Issues	625,466	625,466
Proceeds from Issuance of Common Stock	$ 4,100,000	$ 4,100,000
Cowen and Company, LLC [Member] \| Maximum [Member]
Sale of Stock, Authorized Offering Price				$ 50,000,000

Note C - Debt Obligations (Details Textual) - USD ($)					6 Months Ended
Note C - Debt Obligations (Details Textual) - USD ($)	Jun. 11, 2018	Jan. 31, 2018	Feb. 09, 2016	Jun. 02, 2014	Jun. 30, 2018	Jun. 30, 2016	Dec. 31, 2013
Conversion from Deerfield Convertible Note to Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued	598,568
Debt Conversion, Original Debt, Amount	$ 3,333,333
Debt Conversion, Accrued Interest	$ 168,288
Series D Redeemable Convertible Preferred Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							1,079,453
2021 Notes [Member]
Debt Instrument, Convertible, Conversion Price			$ 17.11
Debt Instrument, Face Amount			$ 86,300,000
Debt Instrument, Interest Rate, Stated Percentage			5.50%
Proceeds from Debt, Net of Issuance Costs			$ 82,800,000
Repayments of Long-term Debt, Total			18,600,000
Debt Instrument, Sinking Fund Payment			$ 0
Debt Conversion, Converted Instrument, Shares Issued			58.4454
Debt Conversion, Original Debt, Amount			$ 1,000
Debt Instrument Repurchase Price Equal to Percentage of Principal Amount			100.00%
Deerfield Facility Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity				$ 60,000,000
Line of Credit Facility, Interest Rate at Period End				9.75%
Debt Covenant, Debt Financing Restriction				$ 750,000
Deerfield Facility Agreement [Member] \| IPO [Member]
Reclassification of Common Stock Shares				256,410
Deerfield Facility Agreement [Member] \| Deerfield Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.78
Deerfield Facility Agreement [Member] \| Deerfield Warrant [Member] \| IPO [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				1,923,077
Deerfield Facility Agreement [Member] \| Series D Redeemable Convertible Preferred Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				14,423,076
Own-share Lending Arrangement, Shares, Issued				1,923,077
Mandatorily Redeemable Preferred Stock, Fair Value Disclosure				$ 1,500,000
Deerfield Facility Agreement [Member] \| Term Notes [Member]
Proceeds from Secured Notes Payable				15,000,000
Deerfield Facility Agreement [Member] \| Deerfield Convertible Notes [Member]
Proceeds from Secured Notes Payable				$ 10,000,000
Debt Instrument, Convertible, Conversion Price				$ 5.85
Third Line of Credit Agreement [Member] \| City National Bank of Florida [Member]
Line of Credit Facility, Maximum Borrowing Capacity						$ 1,100,000
Line of Credit Facility, Remaining Borrowing Capacity					$ 400,000
Long-term Line of Credit, Total					$ 0
Line of Credit Facility, Expiration Period		2 years
Third Line of Credit Agreement [Member] \| City National Bank of Florida [Member] \| Prime Rate [Member]
Debt Instrument, Interest Rate, Stated Percentage					3.98%
Debt Instrument, Basis Spread on Variable Rate					2.00%

Note D - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Loss Contingency Accrual, Ending Balance	$ 0	$ 0

Note E - Preferred Stock and Warrants (Details Textual) - USD ($) $ / shares in Units, $ in Millions		12 Months Ended
	Jun. 02, 2014	Dec. 31, 2013	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017
Preferred Stock, Shares Authorized			10,000,000	10,000,000	10,000,000
Preferred Stock, Shares Outstanding, Ending Balance			0	0	0
Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		143,466
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 5.85
Series D Redeemable Convertible Preferred Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,079,453
2013 Warrants [Member]
Class of Warrant or Right Issued		1,079,453
Deerfield Warrant [Member]
Class of Warrant or Right Issued	14,423,076
Deerfield Warrant [Member] \| Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,923,077
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 5.85
Convertible Notes Payable [Member]
Debt Instrument, Face Amount		$ 3.8

Note F - Common Stock and Warrants (Details Textual) - USD ($)	6 Months Ended	21 Months Ended
	Jun. 30, 2018	Jun. 30, 2018	Dec. 31, 2017	Apr. 30, 2015
Common Stock, Shares Authorized	250,000,000	250,000,000	250,000,000	250,000,000
Common Stock, Shares, Issued, Total	15,905,146	15,905,146	14,657,430
Stock Issued During Period, Shares, New Issues	625,466
Cowen and Company, LLC [Member]
Stock Issued During Period, Shares, New Issues	625,466	625,466
Proceeds from Issuance of Common Stock	$ 4,100,000	$ 4,100,000

Note F - Common Stock and Warrants - Reserved Authorized Shares of Common Stock for Future Issuance (Details) - shares	Jun. 30, 2018	Dec. 31, 2017
Common shares reserved for future issuance (in shares)	12,575,694	12,618,711
Warrant [Member]
Common shares reserved for future issuance (in shares)	2,027,763	2,027,763
Stock Compensation Plan [Member]
Common shares reserved for future issuance (in shares)	3,682,996	2,853,924
Possible Future Issuances Under Equity Incentive Plans [Member]
Common shares reserved for future issuance (in shares)	675,897	944,700
2021 Notes [Member]
Common shares reserved for future issuance (in shares)	5,040,914	5,040,914
Convertible Notes Payable [Member]
Common shares reserved for future issuance (in shares)	1,148,124	1,751,410

Note F - Common Stock and Warrants - Common Stock Activity (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Balance (in shares)			14,657,430
Common stock sold under the ATM Agreement (in shares)			625,466
Common stock issued as a result of Deerfield Convertible Note principal and interest conversion (in shares)			598,568
Common stock options exercised (in shares)	22,375	9,750	23,682	9,750
Balance (in shares)	15,905,146		15,905,146

Note G - Stock-based Compensation (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	22,375	9,750	23,682	9,750
Allocated Share-based Compensation Expense, Total	$ 1,380	$ 1,165	$ 2,659	$ 2,254
Research and Development Expense [Member]
Allocated Share-based Compensation Expense, Total	412	340	787	631
Performance Shares [Member] \| Research and Development Expense [Member]
Allocated Share-based Compensation Expense, Total	$ 0	$ 0	$ 0	$ 0
2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	4,018,480		4,018,480
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Reserved for Issuance, Incremental Percentage of Capital Stock Outstanding			4.00%
Increase in Common Stock Reserved for Issuance			586,297

Note G - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Stock based compensation expense	$ 1,380	$ 1,165	$ 2,659	$ 2,254
Research and Development Expense [Member]
Stock based compensation expense	412	340	787	631
General and Administrative Expense [Member]
Stock based compensation expense	$ 968	$ 825	$ 1,872	$ 1,623

Note H - Fair Value of Financial Instruments (Details Textual) - Fair Value, Inputs, Level 3 [Member] - Deerfield Facility Agreement [Member] - USD ($) $ in Millions	Jun. 30, 2018	Dec. 31, 2017
Deerfield Convertible Notes [Member]
Long-term Debt, Fair Value	$ 8.6	$ 11.0
Term Notes [Member]
Long-term Debt, Fair Value	$ 60.5	$ 51.9

Note H - Fair Value of Financial Instruments - Reconciliation of Beginning and Ending Balances for Derivative and Warrant Liability Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Balance as of beginning of period	$ 17,450	$ 11,834	$ 7,709	$ 4,618
Adjustment to fair value	(5,562)	(3,523)	4,179	3,693
Balance as of end of period	$ 11,888	$ 8,311	$ 11,888	$ 8,311

Note I - Net Earnings Per Share - Anti-dilutive Securities (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Antidilutive securities (in shares)	8,828,596	11,692,975	11,899,797	11,692,975
Warrants to Purchase Common Stock [Member]
Antidilutive securities (in shares)	104,686	2,027,763	2,027,763	2,027,763
Stock Compensation Plan [Member]
Antidilutive securities (in shares)	3,682,996	2,873,344	3,682,996	2,873,344
Convertible Debt Securities [Member]
Antidilutive securities (in shares)		1,750,954	1,148,124	1,750,954
2021 Notes [Member]
Antidilutive securities (in shares)	5,040,914	5,040,914	5,040,914	5,040,914

Note I - Net Earnings Per Share - Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Net loss	$ (9,993)	$ (6,517)	$ (36,212)	$ (22,839)
Less: Net loss allocable to participating securities
Net loss allocable to shares of common stock	(9,993)
Less: Dividends declared or accumulated
Undistributed net loss allocable to shares of common stock, basic	$ (9,993)
Basic (in shares)	15,317,536	14,649,586	15,056,161	14,648,291
Basic (in dollars per share)	$ (0.65)	$ (0.44)	$ (2.41)	$ (1.56)
Net loss	$ (9,993)	$ (6,517)	$ (36,212)	$ (22,839)
Less: Fair value adjustment income related to Deerfield Warrant liability	(2,615)
Add back: Total interest expense related to Deerfield Convertible Note	409
Less: Fair value adjustment income related to embedded Deerfield Note Put Option	(2,923)
Net loss allocable to shares of common stock, diluted	$ (15,122)
Weighted average number of shares of common stock outstanding (in shares)	15,317,536	14,649,586	15,056,161	14,648,291
Dilutive effect of Deerfield Warrant (in shares)	79,000
Dilutive effect of Deerfield Convertible Note (in shares)	1,152,000
Weighted average number of shares of common stock outstanding, diluted (in shares)	16,548,751	14,649,586	15,056,161	14,648,291
Diluted (in dollars per share)	$ (0.91)	$ (0.44)	$ (2.41)	$ (1.56)

Note H - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Financial liabilities measured at fair value on recurring basis	$ 11,888	$ 7,709
Financial assets measured at fair value on recurring basis	11,702	34,608
Certificates of Deposit [Member]
Financial assets measured at fair value on recurring basis	1,217	5,616
US Treasury Securities [Member]
Financial assets measured at fair value on recurring basis	10,485	25,988
US Government Corporations and Agencies Securities [Member]
Financial assets measured at fair value on recurring basis		3,004
Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis
Financial assets measured at fair value on recurring basis	11,702	31,604
Fair Value, Inputs, Level 1 [Member] \| Certificates of Deposit [Member]
Financial assets measured at fair value on recurring basis	1,217	5,616
Fair Value, Inputs, Level 1 [Member] \| US Treasury Securities [Member]
Financial assets measured at fair value on recurring basis	10,485	25,988
Fair Value, Inputs, Level 1 [Member] \| US Government Corporations and Agencies Securities [Member]
Financial assets measured at fair value on recurring basis
Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis
Financial assets measured at fair value on recurring basis		3,004
Fair Value, Inputs, Level 2 [Member] \| Certificates of Deposit [Member]
Financial assets measured at fair value on recurring basis
Fair Value, Inputs, Level 2 [Member] \| US Treasury Securities [Member]
Financial assets measured at fair value on recurring basis
Fair Value, Inputs, Level 2 [Member] \| US Government Corporations and Agencies Securities [Member]
Financial assets measured at fair value on recurring basis		3,004
Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis	11,888	7,709
Financial assets measured at fair value on recurring basis
Fair Value, Inputs, Level 3 [Member] \| Certificates of Deposit [Member]
Financial assets measured at fair value on recurring basis
Fair Value, Inputs, Level 3 [Member] \| US Treasury Securities [Member]
Financial assets measured at fair value on recurring basis
Fair Value, Inputs, Level 3 [Member] \| US Government Corporations and Agencies Securities [Member]
Financial assets measured at fair value on recurring basis
Deerfield Warrant Liability [Member]
Financial liabilities measured at fair value on recurring basis	8,461	5,115
Deerfield Warrant Liability [Member] \| Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis
Deerfield Warrant Liability [Member] \| Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis
Deerfield Warrant Liability [Member] \| Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis	8,461	5,115
Embedded Put Option [Member]
Financial liabilities measured at fair value on recurring basis	577	365
Embedded Put Option [Member] \| Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis
Embedded Put Option [Member] \| Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis
Embedded Put Option [Member] \| Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis	577	365
Fundamental Change and Make-Whole Interest Provisions Embedded in 2021 Notes [Member]
Financial liabilities measured at fair value on recurring basis	26	14
Fundamental Change and Make-Whole Interest Provisions Embedded in 2021 Notes [Member] \| Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis
Fundamental Change and Make-Whole Interest Provisions Embedded in 2021 Notes [Member] \| Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis
Fundamental Change and Make-Whole Interest Provisions Embedded in 2021 Notes [Member] \| Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis	26	14
Embedded Deerfield Note Put Option [Member]
Financial liabilities measured at fair value on recurring basis	2,824	2,215
Embedded Deerfield Note Put Option [Member] \| Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis
Embedded Deerfield Note Put Option [Member] \| Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis
Embedded Deerfield Note Put Option [Member] \| Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis	$ 2,824	$ 2,215